ÂÜÀòÂÒÂ×

Dr Christian Schneider has extensive work and investment experience in the areas of diagnostics, medtech and therapeutics from 18 years in positions of increasing responsibility in the life science and venture capital industry.

At Boehringer Mannheim / Roche (Germany, 1992-1995), he developed the first fully automated test for a new prostate cancer marker, free PSA, which is marketed by Roche worldwide.

At Centocor / Johnson&Johnson (USA, 1995-2000), he led the development of a panel of tumor markers in a transatlantic collaboration between Centocor and Boehringer Mannheim/Roche. Later, as a business developer and external research manager, he negotiated license agreements, set up budgets, and managed biopharma development projects.

As a managing partner of venture capital firm PolyTechnos (Germany 2001-2008), he was directly responsible for the investments in and the IPOs of OncoMethylome Sciences (Euronext, 2006: ONCO), Devgen (Euronext, 2005: DEVG) and Jerini (Frankfurt, 2005: JI4). As a support partner, he was further responsible for the investments and exits of Addex (SWIX, 2007: ADXN) and BiPar (USD 500 m trade-sale to Sanofi-Aventis, 2009). He further served as an independent director on the boards of Immunogenes, HepaWash and MagnaMedics. Christian joined Vesalius in 2008. He is fluent in English and German.

Christian holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).